Lu-177 PSMA-617

Phase 3Small molecule

RRadboud University Medical Center

Lu-177 PSMA-617 is one of 4 small molecule programs targeting Renal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal CarcinomaNot yet recruiting

Renal CarcinomaPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Renal Carcinoma

#DrugCompanyPhaseTrials

EXPAREL

Pacira Pharmaceuticals, Inc

Phase 3

1 2

Sacituzumab Tirumotecan

Merck & Co.

Phase 2

1 3

Lu-177 PSMA-617

RRadboud University Medical Center

Phase 3

1 4

Depo-Provera

Eli Lilly

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Renal Carcinoma

NCT06959433

Clinical

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Completed·RRadboud University Medical Center·Phase 1/2·NCT03828838·10 enrolled

Renal Carcinoma1 trial

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Not yet recruiting·—·Phase 3·NCT06959433·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lu-177 PSMA-617. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lu-177 PSMA-617 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lu-177 PSMA-617. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radboud University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRadboud University Medical Center

Lu-177 PSMA-617

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Metastatic Prostate Cancer1 trial

Renal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News